LONDON (Reuters) - GlaxoSmithKline and its partner Theravance said on Friday they had submitted their new combination lung drug - to be known as Breo and Relvar - for regulatory approval in the United States and Europe. The two-in-one inhaled medicine, previously known as Relovair, is a potential successor to GSK's $8 billion-a-year top-seller Advair. (Reporting by Ben Hirschler)
via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment